Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Food Chem ; 332: 127384, 2020 Dec 01.
Article in English | MEDLINE | ID: mdl-32615384

ABSTRACT

Dairy polar lipids (PL) seem to exhibit antiplatelet effects. However, it is not known what molecular species may be responsible. In this study, we confirmed using C30 reversed-phase (C30RP) ultra-high-performance liquid chromatography (UHPLC) coupled to high resolution accurate mass tandem mass spectrometry (HRAM-MS/MS) that fermentation of yoghurts from ovine milk using specific starter cultures altered the PL composition. These lipid alterations occurred concomitant with increased antithrombotic properties of the yoghurts PL fractions against platelet-activating factor (PAF) and thrombin-induced platelet aggregation. Specifically, elevation in phosphatidylethanolamine (PE), sphingomyelin (SM), phosphatidylcholine (PC) and their molecular species were observed following yoghurt fermentation. Furthermore, PC(18:0/18:1), PE(18:1/18:2), SM(d18:0/22:0) and several other molecular species were significantly inversely correlated with the inhibition of PAF and thrombin. These molecular species were abundant in the most bioactive yoghurts fermented by S. thermophilus and L. acidophilus, which suggest that fermentation by these microorganisms increases the antithrombotic properties of ovine milk PL.


Subject(s)
Lipids/analysis , Milk/metabolism , Platelet Aggregation Inhibitors/analysis , Yogurt/analysis , Animals , Blood Platelets/drug effects , Blood Platelets/metabolism , Chromatography, High Pressure Liquid , Fermentation , Lipids/pharmacology , Phosphatidylcholines/metabolism , Phosphatidylethanolamines/metabolism , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/pharmacology , Sheep , Sphingomyelins/metabolism , Tandem Mass Spectrometry , Thrombin/pharmacology
2.
Mol Med Rep ; 15(1): 317-322, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27922665

ABSTRACT

To the best of our knowledge, the present study is the first to demonstrate that treatment of vemurafenib-resistant SKMEL28 (SKMEL28-R) cells with paclitaxel leads to a shift in localization of the E3-ligase BBAP from the cytoplasm to the nucleus, consequently decreasing the metastatic ability of this cell line. The present study revealed that the movement of BBAP from the cytoplasm to nucleus initiated a change in cell morphology. In addition, the translocation of BBAP led to a decrease of metastatic characteristics in SKMEL28­R cells, including migration and invasion via downregulation of the phosphorylated form of focal adhesion kinase and N­cadherin, as well as an upregulation of p21 and E-cadherin. The results of the present study suggested that BBAP may not only be a novel biomarker for melanoma, but also a novel therapeutic target for treatment of metastatic melanoma.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Nucleus/metabolism , Indoles/pharmacology , Melanoma/drug therapy , Neoplasm Metastasis/prevention & control , Paclitaxel/pharmacology , Skin Neoplasms/drug therapy , Sulfonamides/pharmacology , Ubiquitin-Protein Ligases/metabolism , Active Transport, Cell Nucleus/drug effects , Cell Line, Tumor , Cell Nucleus/drug effects , Drug Resistance, Neoplasm , Humans , Melanoma/metabolism , Melanoma/pathology , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Vemurafenib
SELECTION OF CITATIONS
SEARCH DETAIL
...